Current management of pregnancy-associated breast cancer

Hong Kong Med J. 2017 Aug;23(4):387-94. doi: 10.12809/hkmj166049. Epub 2017 Jun 26.

Abstract

Pregnancy-associated breast cancer is the most common malignancy during pregnancy with an expected rise in incidence. The belief in the need for termination of pregnancy and that chemotherapy is contra-indicated during pregnancy is challenged by recent evidence. Patients can consider breast-conserving surgery and sentinel lymph node biopsy with acceptably low fetal risk from radiation exposure. A range of chemotherapeutics is possible in the second trimester in terms of drug class and frequency. Hormonal therapy and monoclonal antibody therapy are contra-indicated during pregnancy and lactation. Fetal outcome after in-utero exposure to chemotherapy appears similar to that in a non-pregnant population. Future pregnancy, in most situations, does not appear to be contra-indicated but a multidisciplinary and patient-centred approach is recommended. Fertility preservation techniques are also being developed with reported success and consequent pregnancies.

Keywords: Breast neoplasms; Pregnancy complications, neoplastic.

Publication types

  • Review

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Breast Neoplasms / therapy*
  • Disease Management*
  • Female
  • Humans
  • Infant, Newborn
  • Mastectomy, Segmental / adverse effects
  • Maternal Exposure / adverse effects
  • Pregnancy
  • Pregnancy Complications, Neoplastic / therapy*
  • Sentinel Lymph Node Biopsy / adverse effects